Market Assessment
MediciNova (MNOV) is a small-cap ($401M), clinical-stage biopharma with a diverse clinical program. Its primary focus is the clinical development of the lead investigative drug candidate, MN-166, currently in early-mid-phase clinical trials for several neurological diseases, including multiple sclerosis, amyotrophic lateral sclerosis ((ALS)), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma. MN-001, tipelukast, is in clinical development for fibrotic diseases, Idiopathic pulmonary fibrosis and NASH, the focus of this article.
The complex pathophysiological pathways for NASH disease in addition to the diverse histopathological patient population have both made the clinical